Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive intermittent enzalutamide for metastatic castration-resistant prostate cancer
ACTRN12619000567123Phase 2Recruiting
- Sponsor
- Calvary Mater Newcastle
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC), sponsored by Calvary Mater Newcastle. Primary endpoint: Tolerability and acceptability of adaptive dosing. Started Aug 2019; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ACTRN12619000567123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000567123.